©2024 Stanford Medicine
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
Recruiting
Trial ID: NCT02462486
Purpose
This is a safety and efficacy study of abicipar pegol in participants with neovascular
age-related macular degeneration.
Official Title
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study)
Stanford Investigator(s)
Theodore Leng, MD, FACS
Associate Professor of Ophthalmology and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine (Adult MSD)
Eligibility
Inclusion Criteria:
- Diagnosis of age-related macular degeneration in at least 1 eye
- Best corrected visual acuity of 20/40 to 20/320 in the study eye
- Best corrected visual acuity of 20/200 or better in the non-study eye
Exclusion Criteria:
- History of vitrectomy, macular surgery, or glaucoma surgery in the study eye
- Cataract or refractive surgery in the study eye within the last 3 months
Intervention(s):
drug: abicipar pegol
drug: ranibizumab
other: sham procedure
Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305